Eli Lilly and Company (LLY)
Eli Lilly: Another Not-To-Miss Dip
Eli Lilly's price fell with a thud yesterday following underwhelming drug trial results as the markets completely ignored strong Q2 2025 results. LLY's drop is immediately reminiscent of a similar plunge for its rival Novo Nordisk a few days ago, and also only makes for a stronger Buy case. The company's position in the weight management market remains undisputed for now; it's also reported robust financials in Q2 2025 along with upgraded guidance.
Is Eli Lilly's 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
Industry pioneer Novo Nordisk A/S NYSE: NVO saw its stock drop nearly 22% on July 29 after lowering its full-year guidance. Then, on Aug. 7, Eli Lilly NYSE: LLY shares fell approximately 14%.
Eli Lilly: 50% Upside For LLY Stock?
On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This positive performance was mainly fueled by the ongoing success of its medications, Mounjaro and Zepbound.
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
It's been a week of wins for Eli Lilly's weight-loss drugs. In the company's second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication often used for weight loss, reached nearly $5.2 billion in revenue, up 68% from the same quarter last year and exceeding analyst estimates of $4.7 billion.
Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here's Why It's Down
Eli Lilly CEO David Ricks told CNBC the company was “not disappointed with these results,” which he noted were “right on thesis for us” despite falling “one or two points below what [Wall Street] had.” Orforglipron's average weight loss was “in the range” of what consumers would want to achieve, Ricks said.
LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
Eli Lilly and Company (LLY) Q2 2025 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Daniel M. Skovronsky - EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology David A.
Jobless Claims Increased More Than Expected
Another full morning of market data to go through today, which will help articulate where we are in several accounts of the massive U.S. economy. Pre-market futures were at peak highs just ahead of new economic prints this morning, but we remain in healthy, positive territory.
Jobless Claims, Q2 Productivity, Q2 Earnings All Higher
Pre-market futures were at peak highs just ahead of new economic prints this morning, but we remain in healthy, positive territory.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Lilly (LLY) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Eli Lilly Weight-Loss Pill Trial Disappoints, Offsetting Solid Profit and Sales
Ely Lilly (LLY) shares sank 14% Thursday when the pharmaceutical firm reported disappointing results from a late-stage study of its experimental obesity pill. The news offset Lilly's strong quarterly results.
